Company Overview and News

 
Record US$2.2b Hong Kong land sale shows market still hot

2017-11-16 themalaymailonline
A plot of land in Kowloon (pic) has gone for a record HK$17.3 billion to a consortium in the lastest sign of a hot Hong Kong property market. — AFP picHONG KONG, Nov 16 — A consortium including Sino Land Co paid a record HK$17.3 billion (US$2.2 billion or RM9.29 bilion) for a plot of residential land in Hong Kong, signalling the property market is still running hot.

 
Hong Kong company directors’ share buying rises for a second week

2017-10-01 scmp
51 companies recorded 314 purchases by directors worth HK$480 million, while seven firms reported 24 disposals worth HK$400 million.

 
World's costliest plot of land sold in Hong Kong for RM13bil

2017-05-16 thestar.com.my
HONG KONG: Henderson Land Development, the property company owned by one of Hong Kong's wealthiest families, has bought the world's most expensive commercial land plot in downtown Central, beating out the mainland Chinese developers who had been dominating the city's real estate purchases in the past year.

 
Sympathy for the Hong Kong Property Devil - Bloomberg Gadfly

2017-03-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Plot of MTR Corp land next to Wong Chuk Hang station on Hong Kong island draw at least 13 bids

2017-02-27 scmp
At least 13 bids have been submitted by developers have bid for plot of MTR Corp land next to Wong Chuk Hang station, and the old Wong Chuk Hang Estate on Hong Kong island, the tender for which closed at 2pm on Monday.

 
Hong Kong Property Market Sets New Records Despite Moves to Tame Prices - Bloomberg

2017-02-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Chinese funds to move into Hong Kong’s mass housing, push prices to new highs, analysts say

2017-02-26 scmp
Friday’s sale by tender at Ap Lei Chau was a record for the southern district, exceeding market valuation by 50 per cent. The reaction in the market was swift and apparent, with owners and developers raising prices immediately

 
Chinese Group to Pay Record $2.2 Billion for Hong Kong Land - Bloomberg

2017-02-24 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
Mainland developers Logan, KWG win residential site at Ap Lei Chau for higher-than-expected HK$16.86 bn

2017-02-24 scmp
Mainland developers Logan Property Holdings and KWG Property Holding have joined forces to win a residential site in Ap Lei Chau, an island just off Hong Kong, after paying a higher-than-expected HK$16.86 billion (US$2.17 billion).

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...